Data Insights

MT-302 by Myeloid Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Metastatic Colorectal Cancer

Data Insights

MT-302 by Myeloid Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Triple-Negative Breast Cancer (TNBC)

Data Insights

MT-302 by Myeloid Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

MT-302 by Myeloid Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Epithelial Ovarian Cancer

Data Insights

MT-302 by Myeloid Therapeutics for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

MT-302 by Myeloid Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Pancreatic Ductal Adenocarcinoma

Data Insights

MT-302 by Myeloid Therapeutics for Esophageal Cancer: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Esophageal Cancer

Data Insights

MT-302 by Myeloid Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Non-Small Cell Lung Cancer

Data Insights

MT-302 by Myeloid Therapeutics for Gastric Cancer: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Gastric Cancer

Data Insights

MT-302 by Myeloid Therapeutics for Cervical Cancer: Likelihood of Approval

MT-302 is under clinical development by Myeloid Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - MT-302 in Cervical Cancer